Five SNPs showing significant association at genome-wide significance level and one suggestive SNP
| GWAS† | Replication study‡ | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Freq. | Freq. | Meta-analysis§ | ||||||||||||
| SNP¶ | Chromosome | Position (bp)†† | Gene | A1/A2‡‡ | Cases | Controls | OR (95% CI) | p Value | Cases | Controls | OR (95% CI) | p Value | OR (95% CI) | p Value |
| rs2728125 | 4 | 89 001 893 | ABCG2 | C/T | 0.40 | 0.25 | 2.05 (1.80 to 2.34) | 1.5×10−27 | 0.40 | 0.24 | 2.03 (1.79 to 2.30) | 8.3×10−29 | 2.04 (1.86 to 2.23) | 7.2×10−54 |
| rs3775948 | 4 | 9 995 182 | SLC2A9 | G/C | 0.68 | 0.56 | 1.64 (1.45 to 1.86) | 6.7×10−15 | 0.67 | 0.56 | 1.57 (1.40 to 1.77) | 7.6×10−14 | 1.61 (1.47 to 1.75) | 5.5×10−27 |
| rs2188380 | 12 | 111 386 127 | MYL2-CUX2 | T/C | 0.85 | 0.76 | 1.78 (1.52 to 2.08) | 5.7×10−13 | 0.86 | 0.78 | 1.73 (1.48 to 2.02) | 2.0×10−12 | 1.75 (1.57 to 1.96) | 1.6×10−23 |
| rs1260326 | 2 | 27 730 940 | GCKR | T/C | 0.62 | 0.54 | 1.39 (1.23 to 1.57) | 1.2×10−7 | 0.61 | 0.55 | 1.32 (1.18 to 1.49) | 2.8×10−6 | 1.36 (1.25 to 1.48) | 1.9×10−12 |
| rs4073582 | 11 | 66 050 712 | CNIH-2 | G/A | 0.95 | 0.91 | 1.78 (1.39 to 2.29) | 5.3×10−6 | 0.94 | 0.91 | 1.55 (1.23 to 1.96) | 1.6×10−4 | 1.66 (1.40 to 1.96) | 6.4×10−9 |
| rs10791821** | 11 | 65 368 323 | MAP3K11 | G/A | 0.94 | 0.90 | 1.75 (1.38 to 2.22) | 2.8×10−6 | 0.94 | 0.92 | 1.41 (1.12 to 1.77) | 3.4×10−3 | 1.57 (1.33 to 1.85) | 1.0×10−7 |
†945 gout cases and 1213 controls.
‡1048 gout cases and 1334 controls.
§Meta-analyses of the combined GWAS and replication samples (1993 gout cases and 2547 controls).
¶dbSNP rs number. A suggestive SNP is marked with ‘**’.
††SNP positions are based on the National Center for Biotechnology Information human genome reference sequence Build 37.4.
‡‡A1 is a risk-associated allele and A2 is a non-risk-associated allele.
Freq., frequency of A1; GWAS, genome-wide association study; SNP, single-nucleotide polymorphism.